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Abstract  
 
Objective 
Radiotherapy (RT) is effective in preventing heterotopic ossification (HO) around acetabular fractures requiring 
surgical reconstruction.  We audited outcomes and estimated risks from RT prophylaxis, and alternatives of 
indometacin or no prophylaxis. 
 
Methods 
Thirty four patients underwent reconstruction of acetabular fractures through a posterior approach, followed by 
8 Gy single fraction.  Mean age was 44 years.  Mean time from surgery to RT was 1.1 days.   
 
The major RT risk is radiation-induced fatal cancer.  The International Commission on Radiological Protection 
(ICRP) method was used to estimate risk, and compared to a method (Trott & Kemprad) specifically for 
estimating RT risk for benign disease.  These were compared to risks associated with indometacin and no 
prophylaxis. 
 
Results 
Twenty eight patients (82%) developed no HO; 6 developed Brooker Class I, none developed Class II - IV HO.   
 
The ICRP method suggests a risk of fatal cancer in the range of 1-in-1000 to 1-in-10,000; the Trott & Kemprad 
method suggests 1-in-3000.  For younger patients this may rise to 1-in-2000; for elderly patients it may fall to 1-
in-6000.  Risk of death from gastric bleeding or perforation from indometacin is 1-in-180 to 1-in-900, in older 
patients.  Without prophylaxis risk of death from re-operation to remove HO is 1-in-4000 to 1-in-30,000.   
 
Conclusions  
These results are encouraging, consistent with much larger series, and endorse our multidisciplinary 
management.  Risk estimates can be used in discussion with patients.   
Advances in knowledge 
Risk from RT prophylaxis is small, it is safer than indometacin, and substantially overlaps with the range for no 
prophylaxis. 
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Introduction 
Heterotopic ossification (HO) can develop around surgically reconstructed acetabular fractures or hip 
replacements and is an important cause of morbidity.  Radiotherapy (RT) has an established place in prophylaxis 
against HO [1-10].  We have developed a systematic multidisciplinary approach to the management of patients 
with traumatic acetabular fractures.  The fractures are reconstructed surgically, and when a posterior surgical 
approach to the acetabulum has been used, this is followed by RT prophylaxis.  This development has been 
prompted in part by the rising numbers of traumatic acetabular fracture patients presenting here, especially since 
our centre’s designation as a major trauma centre in 2012.  Most of these fractures are the result of road traffic 
accidents (RTAs), which are the commonest cause by far [11].   
 
Operative fixation of displaced acetabular fractures with open reduction and internal fixation has become the 
standard surgical management approach to these fractures [12], and overall, outcomes are improving [13].  HO 
is a particular complication of posterior acetabular fractures, and a posterior surgical approach is an important 
additional risk factor [14].  However, this may be the optimum approach to reduce displaced fragments and 
achieve the best possible anatomical restoration.   
 
The most common symptoms and signs of HO are decreased range of movement and pain.  More severe HO can 
lead to loss of joint mobility with decreased function, and the hip may even become ankylosed.  In these 
circumstances, it is occasionally necessary to remove heterotopic bone, although full excision of the abnormal 
bone is extremely difficult and associated with unacceptable complications such as poor abductor function and 
abnormal gait.  This is a clinical outcome worth avoiding whenever possible.   
 
HO is most commonly quantified using the Brooker classification system [15].  This scores severity from zero 
to IV, where class IV represents ankylosis of the joint, and correlates well with functional outcome [16].  The 
incidence of HO ranges from 2% to 59% [13-15, 17], with severe HO rates of 15%, 21% and 38% in three series 
of patients following surgical reconstruction of acetabular fractures where prophylaxis was not used [7, 8, 18].  
A meta-analysis of 3670 fractures found an overall risk of 26%, with significant HO (Class III or IV) occurring 
in 6%; in the majority (2173 patients), prophylaxis was either not used or not documented [17].  However, the 
risk of grade III & IV HO is higher with the Kocher-Langenbeck (posterior) surgical approach: this was 
specifically reported in the meta-analysis, which suggested a risk of severe HO of 12% [17].  This may be the 
most relevant figure for comparison with our results. 
 
Patients with fractures resulting from RTAs may have a number of other associated injuries.  Some of these, 
including head injuries, may further add to the risk of developing HO [19].  Such injuries also add to the 
complexity of management.  Ventilated patients, for example may be considered more appropriate for post-
reconstruction prophylaxis using indometacin rather than radiotherapy.   An additional issue is that many RTA 
patients are relatively young, raising the question of risk versus benefit from the use of prophylaxis involving 
ionizing radiation.      
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The particular issue of risk from RT prompted us to review our overall management approach.  The first step 
was to audit the outcome of patients treated with our multidisciplinary approach using post-operative RT, to 
ensure that our results matched other larger series.  We also reviewed the published information on efficacy of 
the two established methods of prophylaxis, RT and indometacin.  We then sought to consider the potential risks 
of RT prophylaxis, and to estimate the risks compared to the alternatives of indometacin treatment and no 
prophylaxis.  We present and discuss these estimates of risk. 
 
 
 
Materials and Methods 
 Audit of HO outcomes 
The review of outcomes was registered with the Audit Department.  Data was obtained and analysed in 
accordance with hospital guidelines.  Between 1997 and 2012, 57 patients had radiotherapy for heterotopic 
ossification prophylaxis in our centre.  Of these, 39 patients had undergone surgery for posterior fractures of the 
acetabulum.  Thirty one were treated from 2005 onwards, averaging just under 4 per year, although this number 
appears to be rising, possibly related to major trauma centre designation. 
 
In affected patients, HO increases post-operatively, typically reaching its maximum by about 12 weeks 
following surgery [6, 8, 18].  Thirty-four of the 39 patients had plain X-rays taken 12 weeks or more after 
surgery, and so were suitable for evaluation.  The remaining 5 were lost to follow up, which is a hazard with 
RTA patients who may not live locally.  Twenty five patients (73%) were male and 9 (27%) female.  The mean 
age was 44 years (Figure 1).  Road traffic accidents were the cause of the trauma in 85%.  One fracture was the 
result of a rugby injury, one patient fell from scaffolding, one tripped and fell, and in two the cause of the 
trauma was not recorded.  Twenty five (74%) sustained 1 or more other injuries, including 2 with head injuries.  
 
All 34 patients had major fractures with or without dislocation requiring surgical reconstruction, aimed at 
restoring anatomical integrity.  This allows early mobilisation, reducing morbidity and speeding discharge, and 
also improves the long term outlook [18, 20].  Surgery was carried out as soon as the patient was stable 
following the injury (mean 6 days, range: 0-17 days).  In all patients a posterior Kocher-Langenback approach 
was used to provide optimal access for the reconstruction, and since it is this group who have a particularly high 
risk of developing HO, RT was given postoperatively.  The mean time from surgery to RT was 1.1 days (range 1 
– 5).  Presence and severity of HO were assessed using the Brooker grading system [15] on the latest plain (AP) 
pelvis radiograph.  The average time to the latest follow up plain radiograph was 110 weeks (range 13 – 534 
weeks).  None of the patients was pregnant when treated. 
 
Five additional patients were originally intended to have RT: 4 had other injuries sufficiently serious to preclude 
RT, and the fifth could not be treated with RT within 96 hours, was treated with indometacin instead, and did 
not develop HO.  Where RT prophylaxis is not possible, and provided there are no contraindications, we use 
indometacin 25mg three times a day for 6 weeks as an alternative. 
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The remaining 18 patients (of the 57) had all developed HO and received RT following excision or revision 
surgery.  Three received radiotherapy following surgery to remove heterotopic bone which had formed around 
traumatic femoral fractures; 14 were treated following revision hip replacement and one after revision total knee 
replacement, where HO had developed after the original procedure.  They will not be considered further here.   
 
 Radiotherapy Technique 
Radiotherapy was planned from CT using ProSoma virtual simulator software (OSL, Shrewsbury, UK), except 
for the first few patients for whom a conventional simulator was used.  The CT demonstrates the surgical 
reconstruction, and is therefore routinely passed to the hospital PACS system for review by the surgical team.  
The axial CT can also show the position of the ovary in premenopausal women, allowing confirmation that 
treatment avoids the ipsilateral ovary.   
 
Anterior and posterior opposed fields are used, with the central axis closer to the medial field border to reduce 
divergence medially.  The target includes the acetabular fracture, the musculature proximal to the greater 
trochanter including gluteus minimus [21], the lesser trochanter, and the muscle tissue lateral to the femur, 
excluding the skin laterally.  Multi-leaf collimator shielding is used to reduce the volume treated, and especially 
to minimise dose to the pelvic contents and external genitalia.  Similar fields are reported in other studies [10, 
22].  Figure 2 shows an example of a case in which RT prophylaxis was not given as the result of severe 
additional injuries.  The distribution of the HO is useful in identifying the target volume for treatment.  HO can 
also develop in the musculature lateral to the greater trochanter [22].  The area posterior to the hip joint and neck 
of femur is also at risk.  Indeed, a previous report described a technique to shield the femoral head in the hope of 
reducing late arthritis [22].  However, HO developed in 48% of shielded hips, compared to 20% of those not 
shielded, so this is not recommended.   
Figure 3 shows the RT planning images for a patient who had reconstruction of posterior wall fractures from an 
RTA.  Treatment was planned and delivered the day after surgical reconstruction, which has the advantage that 
the fracture is stabilized and any traction has been removed.  The field shown in Figure 3 is defined as the 50% 
isodose, and must make some allowance for variation in set up on the linac.  Our standard practice is to perform 
an electronic portal image of the anterior field before treatment, and to correct a discrepant position with an 
action level of 0.5 cm.  Testicular shielding has been recommended by some [23], but we prefer to avoid placing 
uncomfortable bulky additional shielding between the legs, which could adversely affect patient positioning. 
A standard single dose of 8 Gy (central axis mid plane) is delivered with a linear accelerator, with energy of 6, 
10 or 15 MV, with one of the higher energies preferred for larger patients.  At the beginning of the prophylactic 
RT programme, a dose of 8 Gy, rather than 7 Gy, was chosen in order to harmonise with other single fraction 
treatments, especially those given for bone metastases, for which 8 Gy is a widely used and evidence-based 
dose.  We prefer to plan and treat the patient the day after surgical reconstruction to minimize the delay (see 
below).  Typically, the patient is more comfortable and confident in moving from bed to scanner and treatment 
couch following reconstruction.  RT is more traumatic prior to the fracture being reconstructed, and timing of 
surgery is sometimes unpredictable.  We therefore prefer to give early RT post-operatively; the reverse is true 
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for revision hip replacement prophylaxis, when pre-operative RT is more comfortable and convenient for the 
patient.   
 
Although non-union can occur with RT, this is less relevant where internal reconstruction has been performed, 
and can also occur with indometacin [23, 24].  RT does not affect healing of other fractures, unlike systemic 
indometacin [24]. 
 
 Estimates of risk 
We sought to estimate the risk of fatal complications from 3 potential treatment strategies, namely RT 
prophylaxis, prophylaxis with indometacin, and no prophylaxis.  The most important risk associated with RT for 
HO is fatal radiation-induced cancer.  However, a risk of death is also associated with indometacin therapy, 
even of short duration, particularly from gastro-intestinal complications.  In addition, there is a (small) risk of 
death associated with re-operation in patients who go on to develop severe HO.  We have not attempted to 
address non-fatal side effects, nor to estimate effects of HO on quality of life. 
 
  Estimating risk from RT 
A method to estimate the risk of fatal radiation-induced malignancy over the lifetime of the patient is provided 
by the International Commission on Radiological Protection (ICRP) [25].  It is based largely on epidemiological 
studies of individuals exposed to whole body low dose irradiation, particularly survivors at Hiroshima and 
Nagasaki, and provides an estimate of global population risk, irrespective of age.  However, this is designed 
explicitly for use in protection.  Although not intended for application to the risks from therapeutic exposure, it 
does provide a methodology which considers different tissues and different volumes of tissue.  The method 
involves calculating the mean organ dose for relevant organs at risk, multiplying this by an organ weighting 
factor [25], summing these and finally multiplying by the recommended risk factor. We assumed 8 Gy exposure 
to 2% of the bone marrow and bone surface and 1% of the skin and muscle, with ICRP tissue-weighting factors 
of 0.12 for marrow and 0.01 for these other tissue.  The risk factor is normally quoted as 5% per sievert (Sv) 
[25].  However, this applies to the whole population, including children, and the ICRP suggests a risk factor of 
4.1% per Sv for an adult population.  However, the ICRP method is explicitly not intended for prediction of 
risks from therapeutic radiation [25], and moreover, it is thought to over-estimate the risk, possibly by as much 
as 1 – 2 orders of magnitude [26, 27].  We have not attempted to model scattered doses [28].   
 
Another approach is to consider the number of cases of malignancy in patients treated with RT, for either 
malignant or benign tumours, although most series relate to treatment of malignancy.  Case reports of 
malignancy related to RT for HO prophylaxis, whilst important, do not provide estimates of incidence since no 
denominator of unaffected cases can be provided.   
 
Trott & Kemprad [26] developed a procedure specifically for estimating cancer risks after radiotherapy of non-
malignant diseases by using direct evidence derived from epidemiologic data in patients who were treated using 
irradiation in the past.  They included allowance for field size and modifying factors, such as risk genes like 
retinoblastoma, to produce risk estimates relevant to clinical situations such as RT prophylaxis against HO.   
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 The difference in risk for different age at exposure is difficult to assess, although some data are available from 
the National Research Council of the National Academies BEIR VII Phase 2 report [29]. This comprises data on 
estimates of risk of death from cancer attributable to whole body radiation exposure according to age at 
exposure, from birth to age 80.  The most relevant data relates to risk of ‘other’ tumours, which excludes central 
pelvic and thoracic tumours, and breast cancer.   
 
  Estimating the risk from use of indometacin 
Estimates of risk are based on published series of patients taking indometacin, or similar drugs, who develop 
complications, often concentrating on older patients who are at higher risk.  We sought reports which might 
provide risk estimates, although have not undertaken a systematic literature review.  These have been combined 
with surgical estimates of risk of death from the known major gastro-intestinal complications of perforation and 
haemorrhage. 
 
  Estimating the risk from use of no prophylaxis 
Although slightly artificial, a risk of death can be considered to exist for patients who develop severe HO, since 
a proportion may require further surgery to reduce morbidity, carrying a risk of peri-operative death.  Estimates 
are based on the incidence of severe HO, the proportion requiring surgery, and estimates of risk for elective 
surgery. 
 
Results & Discussion 
 Results of clinical series 
In our small series of 34 patients, plain radiographs demonstrated that 28 (82%) patients developed no 
heterotopic ossification.  Six (18%) developed Brooker Class I HO and none developed Class II, III or IV.  One 
of the patients with Brooker Class I HO had the additional risk factor of an associated head injury.  These results 
compare favourably with the published risk of severe HO of 1 in 8 (12%) in patients requiring a posterior 
surgical approach [17], even though our series is small.  As noted above, 5 patients were unable to receive RT: 2 
received indometacin, one remaining free from HO, the other developing grade III HO; 3 had no prophylaxis 
and developed grade I, grade III and grade IV HO.  This provides endorsement for the use of prophylaxis, as 
discussed below. 
 
 RT and indometacin as prophylaxis against HO 
The clinical features of ankylosis and reduced function only appear in grade III and above.  Therefore, 
prophylactic therapy is aimed at reducing significant HO of a higher degree [16].  Timing and dose of 
prophylactic radiotherapy have been established over some years, with large randomized controlled trials 
providing robust data.  Early reports of RT as HO prophylaxis typically used modest doses such as 20Gy in 10 
fractions, similar to schedules known to impair bone growth [1].  In historical cohorts, 10Gy in 5 fractions was 
found to be as effective as 20Gy in 10 fractions [2].  A randomised trial of post-operative RT demonstrated no 
difference between 10Gy in 5 fractions and 17.5Gy in 5 fractions [4], endorsing the lower dose.  Subsequent 
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studies have shown that single fractions are just as effective, provided doses of 7 Gy or more are used [2, 3, 5, 
10].   
 
No difference in outcome was found in patients randomised to pre-operative RT (≤ 4 hours before surgery) or 
post-operative RT (≤ 96 hours post-op) [4].  However, delays beyond 3 – 4 days have higher rates of HO [7], 
with rates rising dramatically for delays of more than 3 weeks [10]. 
 
Indometacin has also been used for prophylaxis, but appears less effective.  In a randomised trial, 301 patients 
received postoperative RT with either 5 or 7 Gy or indometacin [5].  Overall rates of HO were 30.1%, 11.1% 
and 16.0% respectively.  Statistically 5Gy was least effective, and 7Gy and NSAID were equivalent.  However, 
for HO grades III and IV, 7Gy was significantly more effective than NSAID, though both treatments had low 
rates (0% versus 1.7%).  Rates of severe HO after surgery and RT of 9% compared to 18% for indometacin [6], 
and 4% versus 11% [8] have been reported.  Sixteen patients who did not receive prophylaxis all developed HO, 
38% with grade III or IV [8].  In a meta-analysis based on 5 prospective studies, describing 384 patients, the 
incidence of Grade III and IV HO was significantly lower in patients treated with RT (3%, 5 of 160) than those 
who received indometacin (9%, 20 of 224) (p ≈ 0.04) [9].   
There is evidence of efficacy of NSAIDs in preventing HO after hip arthroplasty, with a suggested reduction in 
risk of HO after hip arthroplasty of a half to two thirds [30, 31].  However, there are some clear reports of lack 
of efficacy after reconstruction of acetabular fractures [18, 31-33]. In a randomized study of a six-week course 
of indometacin or no prophylaxis in 107 patients, no statistically significant difference was seen in overall rates 
of HO (47.7% versus 56.8%) or rates of grade II or more [33].  A similar finding was reported in a further 
randomised trial of 121 patients [18].  Indometacin once daily for six weeks was compared to placebo in patients 
with displaced fractures of the acetabulum reconstructed through a Kocher-Langenbeck approach.  There was no 
statistically significant reduction in the incidence of severe (Brooker grade III – IV) HO with the use of 
indometacin compared to placebo (15.2% in the indometacin group, 19.4% for placebo).  Based on the results, 
the authors now recommend against the use of indometacin for HO prophylaxis [18, 32].  Problems of 
compliance with indometacin treatment have also been reported [6, 18].  Overall, these data suggest that 
radiotherapy is more effective than NSAID, provided doses of 7Gy or more are used. 
This approach of using RT as prophylaxis against HO in high risk surgical cases appears to be uncommon in the 
UK.  In an informal survey, with responses from 30% of UK centres, no other centre is using RT is this way.  
One centre reported using RT as HO prophylaxis after repair of fractures around the elbow, and 47% have used 
RT after revision hip surgery when HO is known to have occurred. 
 
Overall, the results of this small series, especially the complete absence of any patients with severe HO, 
compare favourably with large published series [2-10, 13-15, 17].  They provide a context for estimates of risk 
and endorse our multidisciplinary approach of meticulous surgical reconstruction and post-operative RT.  Where 
this is operationally or clinically impossible, indometacin 25mg three times a day for 6 weeks has been used, but 
is not favoured in older patients.   
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 Estimate of risk from RT 
In this context, the major risk from RT is malignancy.  The ICRP methodology [25], with a risk factor of 4.1% 
per Sv for an adult population, provides an upper limit for the risk of fatal radiation-induced malignancy over 
the lifetime of the patient.  Using this method, the estimated risk from RT for HO prophylaxis at the hip is 
around 0.092%, or 1 in 1092 (Table 1).  For practical purposes of patient information, rounding to a risk of 1 in 
1000 is appropriate.  This risk is delayed by an average of approximately 15 years [34, 35].  However, the ICRP 
method is explicitly not intended for prediction of risks from therapeutic radiation [25].  It provides an estimate 
of global population risk, irrespective of age.  It is also thought that the method may over-estimate the risk, 
possibly by as much as 1 – 2 orders of magnitude [26, 27].  Assuming the more conservative level of over-
estimate reduces the risk of RT-related death to 1 in 10,000, although it may be even lower.  These figures 
provide estimates of the likely upper and lower limits of risk (Figure 3).    
 
Another approach is to consider the number of cases of malignancy in patients treated with RT, for either 
malignant or benign tumours, although most series relate to treatment of malignancy. Although rare, the 
incidence of radiation-induced sarcoma (RIS) after RT, using high cancer treatment doses rather than low 
prophylaxis doses, has been estimated to be around 0.1% (i.e. 1 in 1000) [36], although may be half that, 1 in 
2000, in patients treated with megavoltage RT [36].  This is consistent with a report [37] of soft tissue sarcomas 
(n=20) and osteosarcomas (n=27) arising in 38,000 patients treated with orthovoltage radiotherapy for a variety 
of benign and malignant conditions, including retinoblastoma, over 50 years.  Ten of these arose in individuals 
treated as children.  Interestingly, and relevant to the issue of HO prophylaxis, no cases occurred with doses less 
than 30Gy.   
 
There are two reports of radiation-induced sarcoma post HO prophylaxis. One patient received 2 x 7 Gy and 
developed sarcoma after 18 years [38] and the second had a single 7 Gy and developed sarcoma after 11 years 
[39].  These reports are important but do not provide estimates of incidence since no denominator for unaffected 
cases is provided.   
 
The method of Trott & Kemprad [26], developed specifically for estimating cancer risks after radiotherapy for 
benign disease, is highly relevant.  The main tissues at risk are the bone, muscle and other soft tissue, and bone 
marrow.  Taking the risk for radiation-induced sarcoma after treatment of benign disease as 1 in 100,000 [26], 
with the risk for induction of leukaemia as 1 in 3125 (assuming 2% of the bone marrow exposed), and the 
leukaemia risk estimate as 0.2% per 1 Gy whole marrow exposure [26]), gives an estimated risk of 1 in 3000.  
This risk estimate falls within the range estimated above, using the ICRP methodology.  Were there to be a 
small incidence of severe HO requiring surgery, the additional risk associated with surgery makes a negligible 
difference to these estimates.   
 
The motivation for attempting to estimate risk was prompted by the recognition that some of the patients 
requiring consideration of RT prophylaxis are relatively young (Figure 1).  Specifically, in our patient group the 
mean age was 44, 15 (44%) were under 40, 5 (15%) were under 30, and the youngest patient treated was only 
21.  This led to the additional need to evaluate risk for different ages at exposure, although this is notoriously 
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difficult to assess.  Some data are available from the National Research Council of the National Academies 
BEIR VII Phase 2 report [29].  The most relevant data are for ‘other’ tumours, thus excluding central pelvic and 
thoracic tumours, and breast cancer, an important risk organ for whole body exposure in women.  Normalizing 
to our mean age of 44, the BEIR data suggest a small increase in risk for patients below 30 and a large reduction 
in risk for older patients.  Taking a risk of 1 in 3000 as the starting point, these numbers convert to 1 in 1900 or 
1 in 6400 for a patient of 20 or 70 respectively.  For simplicity, these could be rounded to 1 in 2000 or 1 in 
6000.   
 
 Estimating the risk from use of indometacin 
Indometacin is the only drug proven to be effective against the development of HO following acetabular 
surgery.  It is considered the gold standard NSAID for HO prophylaxis [23, 40], although other non-steroidal 
anti-inflammatory drugs (NSAIDs) have been used [30, 31], and may be effective after hip arthroplasty [40].  
There is some evidence of efficacy, as noted above, but his has not been consistently replicated [18, 31-33]. 
 
However, indometacin also appears to be amongst the most toxic of the NSAID drugs [41].  In their meta-
analysis of NSAIDs, Fransen + Neal [30] identified 5% of patients to have experienced gastro-intestinal 
toxicity, including 1.5% with serious toxicity.  They were unable to comment on the risk of death.  A separate 
review [42] reported that there was clear evidence that NSAIDs increase the early risk of upper gastrointestinal 
complications, suggesting that patients taking a short course are not be exempt.  They also reported that “only” 
2% of upper gastrointestinal complications were recorded as being fatal.  Indometacin is also associated with a 
risk of non-union in fractures away from the hip [23, 24], which is relevant for patients experiencing poly-
trauma such as occurs with RTAs. 
 
Here, only risk of immediate death from intestinal perforation or haemorrhage will be considered, although 
other adverse effects occur and may be serious [43, 44].  In patients aged 65 and over who were admitted with 
peptic ulcer or upper GI bleeding following non-aspirin NSAID use, 53% had at least one serious complication 
and 11% required surgery [45].  The greatest risk was in the first month, a time frame analogous to HO 
prophylaxis.  Patients of 60 and over who used NSAIDs were 4.7 times more likely than non-users to die from 
ulcer disease [46].  In a meta-analysis of 16 studies on serious GI complications [47], NSAID users were 
roughly 3 times more likely to have a serious GI complication than non-users, with increased risk in patients of 
60 and over, and in the first few weeks of administration.  The overall prevalence of serious gastrointestinal 
complications was 1 per 1000 in the first year [47].   
 
Some of the reservations about indometacin were illustrated in a randomized, prospective double-blind placebo-
controlled clinical trial of the drug after the operative treatment of acetabular fractures [18].  Overall, 53% 
developed HO, which was severe in 17.3%.  No significant difference in the incidence of HO was found 
between indometacin and placebo groups.  However, 20% of the indometacin patients withdrew because of side 
effects which were serious in 3% (one haemorrhage and one perforated ulcer).  Compliance with the medication 
was also problematic, an issue also noted by others [6].  This, combined with the rate of complications, led the 
authors to terminate the study early, and recommend against the use of indometacin in HO prophylaxis.  Others 
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have used misoprostol to aid in prevention of GI complications, although its routine use remains controversial 
[44].   
 
Taking a figure of 11% of patients (≥ 65 years) requiring surgery [45], and assuming a 1% peri-operative 
mortality, gives an estimated mortality of 1 in 900 (Table 1).  This assumes that every patient with life-
threatening complications reaches the operating theatre alive.  This risk is immediate and matches the figure for 
serious GI complications from Gabriel et al [47].  This is consistent with a risk of death of 2% in patients 
experiencing GI complications [42], if about half of patients taking the drugs experience these [45].  Some 
sources suggest that the risk in emergency surgery for perforation or haemorrhage may be rather higher, in the 
range 5-10% [48, 49].  Taking a 5% figure increases the risk to 1 in 180, at least in the over 60s.  The additional 
risk associated with surgery for HO resulting from failed indometacin prophylaxis makes little difference to 
these estimates.   
 
In our series, 21% of patients were 60 or over, and the oldest was a man of 72.  The risk in older patients is 
fairly clear, and remarkably high, even with short exposure.  Unfortunately, data do not appear to exist (or be 
available) on the risk at younger age.  Qualitatively, it appears to be less, perhaps considerably less, than in older 
patients.  Nevertheless, the efficacy of indometacin treatment may also be less than RT, and compliance remains 
a concern. 
 
 Estimating the risk from use of no prophylaxis 
Although slightly artificial, a risk of death can be considered to exist for patients who develop severe HO, since 
a proportion may require further surgery to reduce morbidity, carrying a risk of peri-operative death.  In the 
meta-analysis, the overall risk of severe HO following surgery using the Kocher-Langenbeck approach was 
11.6% [17].  The mean delay before reoperation was 2 years [17].  In another large series, 22.5% patients who 
developed severe HO required further surgery, with a mean interval of 24 months [14].  Combining these 
suggests that 2.6% of patients without prophylaxis (or with failed prophylaxis) would need re-operation.  If the 
risk of peri-operative death is 1%, this gives an upper limit of risk of around 1 in 4000 (Table 1).  A systematic 
review of peri-operative mortality [50] suggested an overall risk of peri-operative death of 0.12%.  Using this 
figure suggests a risk of around 1 in 30,000.  This does not include the risk of malignancy from RT given as 
prophylaxis after second surgery, but since only 2.6% of patients are estimated to require second operation, this 
does not materially change the overall estimates. 
 Comparing risk estimates  
These methods can achieve a population estimate of risk, within broad limits.  The use of a range of risk 
acknowledges the uncertainty but at the same time provides at least approximate limits on the upper and lower 
values of risk.  For RT prophylaxis the risk estimates are in the range 1 in 1000 to 1 in 10,000, and the treatment 
is effective (Table 1).  The risk of developing severe HO after a posterior Kocher-Langenbeck surgical approach 
without prophylaxis is reported to be about 1 in 8.  The risks associated with re-operation for severe HO are in 
the range 1 in 4000 to 1 in 30,000, the exact figure depending on the mortality rate for elective surgery.  These 
ranges overlap considerably, emphasizing their similarity, and also indicating the difficulties in providing 
precise estimates of risk.  The absolute risks are small, lower by several orders of magnitude than the lifetime 
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risk from spontaneous cancer, which is about 1 in 3, and, assuming a global 50% cure rate, a risk of death of 1 in 
6.   
 
The risk associated with indometacin prophylaxis is rather high, at least in older patients.  Some authors have 
reported stopping this form of treatment because of observed complications [18].  Our current work to estimate 
the risks of different approaches has influenced our practice such that we avoid indometacin wherever possible, 
and certainly in older patients. 
 
This work was driven by the clinical need for us to evaluate our practice and also to provide information to 
patients considering RT prophylaxis.  This was relevant for younger patients in whom RT risks might be larger 
and older patients in whom indometacin risks might be higher.  These results, together with the review of 
published work from large series, have allowed us to provide more balanced recommendations to patients, and 
underpin our clinical protocol for multidisciplinary management. 
 
Conclusions  
Our clinical results of multidisciplinary management of patients with traumatic pelvic fractures are encouraging 
and compare well with published studies, with a minority of patients developing only Grade I HO, and none 
suffering severe grades.  We attribute this to early intervention with meticulous surgical technique and 
reconstruction, followed by timely post-operative radiotherapy.  Estimates of risk of death from fatal radiation-
induced malignancy are in the range of 1 in 1000 to 1 in 10,000, with 1 in 3000 being a credible mid-range 
figure.  For younger patients this might rise to 1 in 2000, while for older patients it may fall to 1 in 6000.  This is 
substantially lower, by several orders of magnitude, than the lifetime risk of spontaneous cancer.  Prophylaxis 
with indometacin is less effective with a higher risk of death from complications, of 1 in 900 or more.  Omitting 
prophylaxis obviously carries the lowest estimated risk, in the range 1 in 4000 to 1 in 30,000, but with a 1 in 8 
risk of developing severe (grades III-IV) HO.  Overall, the risk from RT prophylaxis is small, and the estimated 
range substantially overlaps with the range for no prophylaxis, suggesting it is safe as well as effective. 
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Figure legends 
 
Figure 1.  Frequency distribution of age of the 34 treated patients.  Mean age was 44.4 years, median 41.5, 
range 21 – 72.  Note that 15 (44%) were aged under 40. 
 
 
 
Figure 2.   
 
Pelvic X-rays of a 37 year old patient who suffered a fracture dislocation of the left hip requiring reconstruction. 
Multiple other injuries, including pneumothorax and compound fractures at the knee, precluded early post-
operative RT, which would otherwise have been recommended.  No alternative prophylaxis was given. 
(a) Postoperative film.  Skin sutures and a catheter can be seen.  
(b) Follow up film at 14 months, with Brooker grade IV HO.  This was evident within weeks of the 
reconstruction.  Note the spur of HO extending from the acetabulum to ankylose the joint (arrowed).  HO had 
also formed posteriorly and can be seen in projection just above the lesser trochanter.  
(c) 8 months following revision total hip replacement, performed at 19 months, with prophylactic RT delivered 
the following day. No HO has reformed. 
 
 
Figure 3.  
(a) Digitally reconstructed radiograph (DRR) showing the RT anterior field projection, in a young woman with a 
complex posterior acetabular fracture dislocation requiring reconstruction, following an RTA.  The ovary, fully 
shielded, is shown in light blue. 
(b) Coronal CT reconstruction with the projection at depth of the anterior treatment field with corner MLC 
shielding, and ovary contour. 
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